PDS Biotech Announces Data From IMMUNOCERV Phase 2 Trial Investigating PDS0101 And Chemoradiotherapy In Cervical Cancer To Be Featured In Oral Presentation At The ASTRO 2023 Annual Meeting
Portfolio Pulse from Happy Mohamed
PDS Biotechnology Corporation (PDSB) announced that data from the IMMUNOCERV Phase 2 clinical trial investigating PDS0101 in combination with standard-of-care chemoradiotherapy for the treatment of locally advanced cervical cancer will be featured in an oral presentation at the ASTRO 2023 Annual Meeting. The research is designed to evaluate the relationship between the levels of circulating HPV viral DNA and the extent of disease, clinical staging, and treatment response in patients with HPV-positive cervical cancer.
August 16, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotech's announcement of the presentation of their Phase 2 trial data at the ASTRO 2023 Annual Meeting could potentially increase investor interest and confidence in the company.
The presentation of positive clinical trial data at a major conference like ASTRO 2023 can increase visibility and credibility of the company's product, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100